This podcast discusses how psychedelics reopen critical periods of learning, and how the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them.
Read moreRisks with Psychedelics
The most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization.
For approximately one-third of the participants, problems persisted for over a year, and for a sixth, they endured for more than three years.
It was found that a shorter duration of difficulties was predicted by knowledge of dose, drug type and lower levels of difficulty reported during the psychoactive experience, while a narrower range of difficulties was predicted by taking the drug in a guided setting.
Read moreIntensity of Psychedelic Experience
A new study suggests that dosage, age, and neuroticism may predict the intensity of a psychedelic experience, whether mystical (positive) or challenging.
Read morePsilocybin and Adverse Childhood Experiences
Psychedelics for OCD?
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Read moreDMT and SSRIs
Additionally, 92% experienced remission from depression.
Read morePsychiatrists Have Positive Attitude Towards Psychedelics
This recent study shows a striking positive shift in attitudes toward the therapeutic potential of hallucinogens among American psychiatrists since 2016, with a majority of responding psychiatrists planning to incorporate hallucinogen-assisted therapy into their practice if regulatory approval is granted.
Read moreNew Psilocybin Research
This recently published study showed that psilocybin use is associated with persisting improvements in mental health and wellbeing.
Read moreMindfulness and Psychedelics
Psychedelics- An Update
Psychedelic Science 2023 brought together 12,000 registrants in Denver, Colorado, four times as many people as the previous conference in 2017, crowning the movement to rehabilitate psychedelics for therapeutic use against depression and other disorders.
Read moreKetamine For Depression
This ketamine trial for resistant depression shows positive results.
The study is the largest to date comparing generic ketamine with placebo in treating severe depression.
Read more